A 58-year-old man with COPD and recent hospitalization presents with fever (38.5°C), productive cough with greenish sputum, and shortness of breath for 3 days. Chest X-ray shows new infiltrates in the right lower lobe. Sputum culture grows a gram-negative rod that is oxidase-positive, non-fermenting, and produces a characteristic fruity odor. The organism is resistant to multiple antibiotics including ceftazidime and fluoroquinolones. Which of the following is the most appropriate initial empiric antibiotic regimen for this patient?

Explanation

## Clinical Diagnosis **Key Point:** The clinical presentation and culture findings are pathognomonic for *Pseudomonas aeruginosa* ventilator-associated pneumonia (VAP) or hospital-acquired pneumonia (HAP). - Gram-negative, oxidase-positive, non-fermenting rod - Fruity (grape-like) odor due to pyoverdine and pyocyanin pigments - Multidrug resistance (MDR) phenotype - Risk factors: COPD, recent hospitalization, ICU exposure ## Treatment Principles for MDR *Pseudomonas aeruginosa* **High-Yield:** Empiric therapy for suspected *Pseudomonas* in HAP/VAP requires **combination therapy** with 2–3 agents from different classes to prevent resistance emergence and ensure adequate coverage. ### Recommended Regimen | Component | Agents | Rationale | |-----------|--------|----------| | Anti-pseudomonal β-lactam | Cefepime, meropenem, or piperacillin-tazobactam | Covers most strains; meropenem preferred if ESBL suspected | | Aminoglycoside | Amikacin or tobramycin | Synergy; penetrates biofilm; once-daily dosing | | Fluoroquinolone | Ciprofloxacin or levofloxacin | Lung penetration; covers atypical organisms | **Clinical Pearl:** In this case, the organism is already resistant to ceftazidime and fluoroquinolones, making **meropenem + amikacin ± ciprofloxacin** the safest choice. Meropenem is preferred over cefepime in carbapenem-resistant strains. ## Why Combination Therapy? 1. **Synergistic bactericidal activity** — aminoglycosides enhance β-lactam penetration into *Pseudomonas* biofilm 2. **Reduced resistance emergence** — dual/triple therapy delays selection of resistant mutants 3. **Improved clinical outcomes** — combination reduces mortality in severe HAP/VAP vs. monotherapy **Mnemonic:** **PAP-CAP** — *Pseudomonas* Aeruginosa Pneumonia requires **C**ombination **A**nti-pseudomonal **P**rotocol. [cite:Harrison 21e Ch 297]